التفاصيل البيبلوغرافية
| العنوان: |
POS1403 CLINICAL CHARACTERISTICS, HEALTH CARE RESOURCE UTILIZATION, AND COSTS ASSOCIATED WITH FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN GERMANY |
| المؤلفون: |
Ding, B., Pignot, M., Garal-Pantaler, E., Villinger, B., Desta, B., Schmidt, K., Golam, S., Stirnadel-Farrant, H., Schwarting, A. |
| المصدر: |
Annals of the Rheumatic Diseases ; volume 81, issue Suppl 1, page 1042-1043 ; ISSN 0003-4967 1468-2060 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
General Biochemistry, Genetics and Molecular Biology, Immunology, Immunology and Allergy, Rheumatology |
| الوصف: |
Background Longitudinal data describing real-world systemic lupus erythematosus (SLE) disease characteristics, health care resource utilization (HCRU), and costs associated with flares in Germany are limited. Objectives To evaluate the clinical characteristics of patients with SLE and estimate the impact of flares on HCRU and costs in a cohort of adults with SLE in Germany. Methods CHaracteristics and impact of flares on clinicAl and econoMic OutcoMes In patients with systemic Lupus Erythematosus: a German Claims Database Study (CHAMOMILE) was an observational, retrospective cohort study. Adult patients with SLE were identified from the German Betriebskrankenkassen health insurance fund database between 1 July 2010 and 31 December 2013, and followed for up to 9 years. Baseline period was defined as the first year since the first quarter with the earliest SLE diagnosis during the identification period, including this quarter. Resource utilization measures included number of hospitalizations, duration of stay, and associated costs per person-year (PY) by follow-up year for patient subgroups defined by flare exposure (no, mild, or moderate/severe flares) during baseline. Cost measures included total PY costs in flare-exposure subgroups. Results Of 2088 patients included in the study, the mean (SD) age was 51.4 (16.1) years and 1767 (84.6%) were female. The most common SLE manifestations were cutaneous (66.8%), osteoarticular (28.7%), and vascular (23.0%). Patients were receiving treatment with glucocorticoids (54.8%), antimalarials (40.2%), nonsteroidal anti-inflammatory drugs (39.1%), and/or immunosuppressants (32.7%). During the baseline period, 750 patients (35.9%) experienced moderate/severe flares, 622 (29.8%) experienced mild flares, and 716 (34.3%) experienced no flares. Patients with no flares or mild flares during the baseline period had similar costs, and a similar number and duration of hospital stays per PY, which remained consistent from baseline up to 9 years of follow-up. Patients with ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/annrheumdis-2022-eular.899 |
| الإتاحة: |
https://doi.org/10.1136/annrheumdis-2022-eular.899Test |
| رقم الانضمام: |
edsbas.D3E340BE |
| قاعدة البيانات: |
BASE |
